Topical CP-690,550 For Chronic Plaque Psoriasis
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00678561 |
Recruitment Status
:
Completed
First Posted
: May 15, 2008
Last Update Posted
: November 23, 2010
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Psoriasis | Drug: CP-690,550 Drug: Placebo Vehicle | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 81 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Double (Participant, Investigator) |
Primary Purpose: | Treatment |
Official Title: | Phase 2A Randomized, Double-Blind, Vehicle-Controlled, Intra-Individual Comparison Trial Assessing Safety, Toleration, Pharmacokinetics And Pilot Efficacy Of 4 Weeks Treatment With Topical CP-690,550 In Chronic Plaque Psoriasis |
Study Start Date : | October 2008 |
Actual Primary Completion Date : | July 2009 |
Actual Study Completion Date : | July 2009 |

Arm | Intervention/treatment |
---|---|
Experimental: 2% CP-690,550 QD |
Drug: CP-690,550
Topical treatment once daily for 28 days
|
Experimental: 0.2% CP-690,550 QD |
Drug: CP-690,550
Topical treatment once daily for 28 days
|
Experimental: 0.02% CP-690,550 QD |
Drug: CP-690,550
Topical treatment once daily for 28 days
|
Experimental: 2% CP-690,550 BID |
Drug: CP-690,550
Topical treatment twice daily for 28 days
|
Experimental: 0.2% CP-690,550 BID |
Drug: CP-690,550
Topical treatment twice daily for 28 days
|
Experimental: 0.02% CP-690,550 BID |
Drug: CP-690,550
Topical treatment twice daily for 28 days
|
Placebo Comparator: Placebo Vehicle QD |
Drug: Placebo Vehicle
Topical treatment once daily for 28 days
|
Placebo Comparator: Placebo Vehicle BID |
Drug: Placebo Vehicle
Topical treatment twice daily for 28 days
|
- target plaque severity score [ Time Frame: 4 weeks ]
- local toleration [ Time Frame: 4 weeks ]
- safety laboratory assays [ Time Frame: 4 weeks ]
- blood levels of drug [ Time Frame: 4 weeks ]
- physician's global assessment of target lesion [ Time Frame: 4 weeks ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Having chronic plaque psoriasis for at least 6 months
- Able to withdraw all prior psoriasis treatments
- Must agree to avoid prolonged exposure to the sun and avoid use of tanning booths or other ultraviolet light sources during the study
Exclusion Criteria:
- Evidence of active, latent, or inadequately treated infection with Mycobacterium tuberculosis
- Pregnant or lactating women
- Unwilling to use appropriate contraceptive methods

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00678561
United States, California | |
Pfizer Investigational Site | |
Irvine, California, United States, 92697 | |
Pfizer Investigational Site | |
San Diego, California, United States, 92123 | |
United States, Illinois | |
Pfizer Investigational Site | |
Chicago, Illinois, United States, 60612 | |
United States, Massachusetts | |
Pfizer Investigational Site | |
Boston, Massachusetts, United States, 02111 | |
United States, Michigan | |
Pfizer Investigational Site | |
Ann Arbor, Michigan, United States, 48109-0314 | |
United States, Minnesota | |
Pfizer Investigational Site | |
Fridley, Minnesota, United States, 55432-3134 | |
United States, Missouri | |
Pfizer Investigational Site | |
Saint Louis, Missouri, United States, 63117 | |
United States, North Carolina | |
Pfizer Investigational Site | |
High Point, North Carolina, United States, 27262 | |
Pfizer Investigational Site | |
WinstoN Salem, North Carolina, United States, 27157 | |
United States, Oregon | |
Pfizer Investigational Site | |
Portland, Oregon, United States, 97223 | |
Pfizer Investigational Site | |
Portland, Oregon, United States, 97239 | |
United States, Texas | |
Pfizer Investigational Site | |
Austin, Texas, United States, 78759 | |
United States, Utah | |
Pfizer Investigational Site | |
Salt Lake City, Utah, United States, 84132 | |
Canada, British Columbia | |
Pfizer Investigational Site | |
Surrey, British Columbia, Canada, V3R 6A7 | |
Canada, Newfoundland and Labrador | |
Pfizer Investigational Site | |
St. John's, Newfoundland and Labrador, Canada, A1C 2H5 | |
Canada, Ontario | |
Pfizer Investigational Site | |
Waterloo, Ontario, Canada, N2J 1C4 | |
Canada, Quebec | |
Pfizer Investigational Site | |
Montreal, Quebec, Canada, H2K 4L5 | |
Pfizer Investigational Site | |
Montreal, Quebec, Canada, H3Z 2S6 | |
Canada | |
Pfizer Investigational Site | |
Quebec, Canada, G1V 4X7 |
Study Director: | Pfizer CT.gov Call Center | Pfizer |
Additional Information:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | Director, Clinical Trial Disclosure Group, Pfizer, Inc. |
ClinicalTrials.gov Identifier: | NCT00678561 History of Changes |
Other Study ID Numbers: |
A3921038 |
First Posted: | May 15, 2008 Key Record Dates |
Last Update Posted: | November 23, 2010 |
Last Verified: | November 2010 |
Keywords provided by Pfizer:
chronic plaque psoriasis, topical treatment |
Additional relevant MeSH terms:
Psoriasis Skin Diseases, Papulosquamous Skin Diseases Tofacitinib |
Protein Kinase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action |